Search form

Latest News

Quidel Receives PMDA Approval for Its Point-of-Care Sofia® Influenza A+B Assay

SAN DIEGO--(BUSINESS WIRE)--May 24, 2017--
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic
testing solutions, cellular-based virology assays and molecular
diagnostic systems, announced today it has received approval from
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for Quidel’s
Sofia® Influenza A+B Fluorescent Immunoassay (FIA) to be used with the
Sofia® Fluorescent Immunoassay Analyzer.

Read More »


Are you a determined, optimistic, team player? Quidel is looking for talented innovators who want to be part of revolutionizing medical diagnostics.

View Current Job Openings


We appreciate your efforts to improve patient care, physician services, and laboratory efficiency. We know that you will appreciate the value that Quidel brings in delivering diagnostics that do not sacrifice accuracy or ease-of-use. Please explore this site for helpful resources and how you can contact us for further support.